Cereblon in health and disease (Q38876495)

7 September 2017

1 reference

title

Cereblon in health and disease (English)

1 reference

7 September 2017

Bernd Nilius

1 reference

7 September 2017

Hyoung Kyu Kim

1 reference

7 September 2017

Tae Hee Ko

1 reference

7 September 2017

Bayalagmaa Nyamaa

1 reference

7 September 2017

Sung Ryul Lee

1 reference

7 September 2017

Nari Kim

1 reference

7 September 2017

Kyung Soo Ko

1 reference

7 September 2017

Byoung Doo Rhee

1 reference

7 September 2017

Chul-Seung Park

1 reference

7 September 2017

Jin Han

1 reference

7 September 2017

publication date

24 June 2016

1 reference

7 September 2017

1 reference

7 September 2017

volume

468

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

1299-1309

1 reference

Ubiquitination-dependent quality control of hERG K+ channel with acquired and inherited conformational defect at the plasma membrane

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Leukoencephalopathy upon disruption of the chloride channel ClC-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Glutamine, glutamine synthetase and Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Thalidomide therapy induces response in relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Modulation of cereblon levels by anti-myeloma agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

FISH and array-CGH analysis of a complex chromosome 3 aberration suggests that loss of CNTN4 and CRBN contributes to mental retardation in 3pter deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Glutamine and cancer: cell biology, physiology, and clinical opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Temporal and spatial mouse brain expression of cereblon, an ionic channel regulator involved in human intelligence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Cereblon is expressed in the retina and binds to voltage-gated chloride channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Inhibition of cereblon by fenofibrate ameliorates alcoholic liver disease by enhancing AMPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Ablation of cereblon attenuates myocardial ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Association of a functional deficit of the BKCa channel, a synaptic regulator of neuronal excitability, with autism and mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Functional modulation of AMP-activated protein kinase by cereblon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Induction of cereblon by NF-E2-related factor 2 in neuroblastoma cells exposed to hypoxia-reoxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced obesity and insulin resistance in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Depletion of the cereblon gene activates the unfolded protein response and protects cells from ER stress-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

CRL4A(CRBN) E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

CFTR: folding, misfolding and correcting the ΔF508 conformational defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Endoplasmic reticulum stress compromises the ubiquitin-proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

21 January 2018

Chloride channelopathies

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Behavioral characterization of cereblon forebrain-specific conditional null mice: a model for human non-syndromic intellectual disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Activity of thalidomide and lenalidomide in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Cereblon is recruited to aggresome and shows cytoprotective effect against ubiquitin-proteasome system dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

The clinical significance of cereblon expression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

IRF4 addiction in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

AMPK in cardiovascular health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

A seizure-induced gain-of-function in BK channels is associated with elevated firing activity in neocortical pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

AMPK in Health and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Mice with deficient BK channel function show impaired prepulse inhibition and spatial learning, but normal working and spatial reference memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Habituation of reflexive and motivated behavior in mice with deficient BK channel function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Conditional protein phosphorylation regulates BK channel activity in rat cerebellar Purkinje neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Hemoxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Primary function analysis of human mental retardation related gene CRBN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

No evidence for a role of CLCN2 variants in idiopathic generalized epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

A third-generation IMiD for MM

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00424-016-1854-1

Control of vertebrate limb outgrowth by the proximal factor Meis2 and distal antagonism of BMPs by Gremlin

21 January 2018

1 reference

12 December 2020

High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase

1 reference

12 December 2020

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

1 reference

12 December 2020

CLCN2 variants in idiopathic generalized epilepsy

1 reference

12 December 2020

What is the functional role of the thalidomide binding protein cereblon?

1 reference

12 December 2020

Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells.

1 reference

12 December 2020

Cereblon expression in multiple myeloma: not ready for prime time

1 reference

12 December 2020

Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen

1 reference

12 December 2020

10.1007/S00424-016-1854-1

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1029319019

0 references

1 reference